Antigen mimicry in vaccine development leverages the concept of designing synthetic antigens or modifying existing ones to resemble those found on pathogens, triggering a protective immune response without exposing the body to the harmful agent. This method is valuable in creating vaccines for viruses or bacteria with complex surface structures or those that are difficult to target directly. By mimicking the appearance of the pathogen, these vaccines stimulate the production of antibodies that recognize and neutralize the actual pathogen upon future exposure. For instance, some vaccines use parts of the pathogen’s surface proteins, which are similar to the natural ones but modified to ensure safety. Antigen mimicry not only enhances the specificity of immune responses but also opens up possibilities for broad-spectrum vaccines that could protect against multiple strains or even species of pathogens, improving global vaccination strategies.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States